In this study, we not only identified that KIFC1 served as a potential biomarker of recurrence in human breast and colon cancers, but we also showed that DNA-damaging treatments significantly increased the phosphorylation of KIFC1-S26 which leads to the survival of centrosome-amplified cancer cells. This evidence concerns the gene KIFC1 and cancer.